Previous 10 | Next 10 |
Fulcrum Therapeutics press release (NASDAQ:FULC): Q1 GAAP EPS of -$0.64 misses by $0.02. Revenue of $2.6M (-45.7% Y/Y) misses by $1.34M. As of March 31, 2022, cash, cash equivalents, and marketable securities were $195.1 million, as compared to $218.2 million as of December 31, 2021...
– In itial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress – – Phase 3 REACH trial of losmapimod in FSHD expected to begin in 2Q 2022 – – Conference c...
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will par...
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2022 fin...
Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...
Presentations highlight potential of losmapimod to slow or stop progression of FSHD Company on track to initiate Phase 3 REACH trial in 2Q 2022 CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmac...
Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial Live webcast March 24, 2022 at 10:00am ET CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharm...
RWS has been correlated with ability to perform activities of daily living and maintain independence Losmapimod shown to improve or preserve function as measured by RWS in two Phase 2 studies, supporting RWS as the primary endpoint in Phase 3 REACH trial Company on track...
Oppenheimer has started the coverage on the clinical-stage biopharmaceutical company Fulcrum Therapeutics (FULC +9.4%) with an Outperform recommendation citing the potential of FTX-6058, an experimental therapy for sickle cell disease (SCD). The analyst Matthew Biegler argues that “we ...
Fulcrum Therapeutics, Inc. (FULC) Q4 2021 Earnings Conference Call March 3, 2022 8:00 A.M. ET Company Participants Christi Waarich - Director of Investor Relations Bryan Stuart - President and Chief Executive Officer Judy Dunn - President of R&D Esther Rajavelu - Chief Financial Officer C...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...